inx-17 Antibody

What is IL-17A and why is it an important research target?

IL-17A is a pro-inflammatory cytokine encoded by the Q16552 gene that plays a critical role in the immune response against pathogens. It is primarily secreted by Th17 cells and is involved in various inflammatory processes . IL-17A has been implicated in the pathogenesis of multiple autoimmune and inflammatory diseases, including psoriasis, psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis .

The recombinant human IL-17A protein typically encompasses amino acids Ile20-Ala155 of the full sequence . Unlike many cytokines that primarily signal through antibody-dependent mechanisms, IL-17A can mediate immune responses through antibody-independent pathways, making it a unique target for investigating alternative immune mechanisms .

How do I choose between polyclonal and monoclonal anti-IL-17A antibodies for my research?

The choice depends on your specific research application:

Polyclonal antibodies (like the goat anti-human IL-17 polyclonal antibody in the search results) recognize multiple epitopes of IL-17A, making them ideal for:

• Maximum detection sensitivity in Western blots

• Immunoprecipitation studies

• Applications where signal amplification is needed

• Detecting IL-17A in fixed tissues for IHC

Monoclonal antibodies (like clone #41802) offer:

• Higher specificity for a single epitope

• Reduced background in some applications

• More consistent lot-to-lot reproducibility

• Potentially better performance in neutralization assays

For critical applications, validate your selected antibody with positive and negative controls relevant to your experimental system.

Which applications are best suited for anti-IL-17A antibodies?

Anti-IL-17A antibodies have been validated for numerous applications in immunological research:

How can I effectively detect IL-17A-producing cells in tissue samples?

IL-17A detection in tissues requires optimized protocols for accurate identification of IL-17A-producing cells:

• Tissue preparation: Immersion-fixed, paraffin-embedded sections yield reliable results when proper fixation protocols are followed .

• Antibody concentration: For IHC, the optimal concentration is typically 1 μg/mL for 1 hour at room temperature using affinity-purified polyclonal antibodies .

• Detection systems: Anti-goat IgG VisUCyte HRP Polymer Antibody systems provide strong signal with minimal background. DAB (3,3'-diaminobenzidine) produces a brown chromogenic signal that contrasts well with hematoxylin counterstain .

• Co-localization studies: Combining IL-17A detection with lineage markers like CD3 clarifies the cellular source. In acne vulgaris lesions, dual immunofluorescence staining reveals IL-17A (green) and CD3 (red) double-positive cells, with nuclei counterstained in blue .

• Comparative analysis: IL-17A+ cells are often less numerous than T-bet+ cells but may outnumber Foxp3+ cells in certain inflammatory conditions, as seen in acne lesions .

What controls should I include when performing IL-17A neutralization assays?

Neutralization assays require rigorous controls to ensure valid interpretations:

• Dose-response curve: Establish a dose-response relationship between recombinant IL-17A and the readout (e.g., IL-6 secretion in NIH/3T3 fibroblasts) .

• Isotype control antibody: Include a matched isotype control (e.g., AB-108-C) at equivalent concentrations to rule out non-specific effects .

• Titration series: Test multiple antibody concentrations to determine the ND50 (neutralization dose at which 50% of IL-17A activity is inhibited) .

• Positive control: Include a known neutralizing antibody if available (the search results indicate goat anti-human IL-17A has a typical ND50 of 0.02-0.12 μg/mL against 15 ng/mL of recombinant IL-17A) .

• Readout validation: Ensure your biological readout (e.g., IL-6 ELISA) is validated within its linear range .

How can I distinguish IL-17A from other IL-17 family members in my assays?

Discriminating between IL-17 family members is crucial for specificity in research:

• Epitope selection: Choose antibodies raised against unique epitopes. High-affinity antibodies like Indikizumab (KD=27.2 pM) demonstrate superior specificity for IL-17A over other family members .

• Cross-reactivity testing: Perform ELISA or Western blot analysis with recombinant IL-17A, IL-17F, and IL-17A/F heterodimer to confirm specificity.

• Isoform-specific assays: When detecting IL-17A in complex samples, consider using sandwich ELISA systems with verified isoform specificity.

• Genetic approaches: For in vivo or cellular studies, complement antibody experiments with genetic knockdown/knockout of specific IL-17 family members.

• Sequence analysis: The human IL-17A protein (Q16552) has distinct sequence features from other family members, particularly in the Ile20-Ala155 region used for immunization .

What are the key methodological considerations for using IL-17A antibodies in flow cytometry?

Flow cytometry with IL-17A antibodies requires specific technical considerations:

• Cell stimulation: For optimal detection, stimulate cells with PMA (50 ng/mL) and calcium ionophore (250 ng/mL) for 16 hours to induce IL-17A production .

• Intracellular staining: IL-17A is primarily detected intracellularly, requiring:

  • Fixation with paraformaldehyde

  • Permeabilization with saponin

  • Blocking of non-specific binding sites

• Secondary detection: For unlabeled primary antibodies, use fluorophore-conjugated secondary antibodies like Allophycocyanin-conjugated anti-goat IgG .

• Gating strategy: Include appropriate isotype controls (e.g., AB-108-C) to establish negative gates .

• Multi-parameter analysis: Combine IL-17A staining with surface markers like CD3, CD4, and CD8 to identify specific Th17 populations.

How does IL-17A contribute to immunopathology in different disease models?

IL-17A plays distinct roles across various inflammatory and autoimmune conditions:

• Psoriasis: Research shows altered expression of IL-17A+ cells in paradoxical psoriasiform reactions compared to classical psoriasis, with associated changes in IFN-gamma, IL-22, and IL-36 gamma levels .

• Acne vulgaris: Immunohistochemical studies demonstrate IL-17A+ cells in early acne lesions, with IL-17A and CD3 double-positive cells indicating T-cell sources. T-bet+ cells typically outnumber IL-17A+ and Foxp3+ cells in these lesions .

• Streptococcus pneumoniae immunity: IL-17A mediates antibody-independent immunity to pneumococcal colonization, challenging traditional views that antibodies are the sole mediators of protection against this pathogen .

• Cancer: Research has examined IL-17A expression in tumor-associated tissues, though the exact role varies by cancer type .

What is the evidence supporting IL-17A as a therapeutic target in inflammatory diseases?

The rationale for targeting IL-17A therapeutically is supported by multiple lines of evidence:

• Mechanistic studies: IL-17A has been demonstrated to stimulate the release of pro-inflammatory cytokines like IL-6 from fibroblasts, contributing to inflammatory cascades .

• Animal models: In the imiquimod-induced psoriasis mouse model, anti-IL-17A antibodies like Indikizumab demonstrate efficacy in reducing the psoriasis index .

• Pharmacological properties: Humanized monoclonal antibodies against IL-17A, such as Indikizumab, show high binding affinity (KD=27.2 pM) and specificity for IL-17A, with demonstrated effectiveness in neutralizing IL-17A effects in vivo .

• Biomarker responses: Treatment with anti-IL-17A antibodies produces statistically significant reductions in inflammatory markers such as plasma KC (Keratinocyte) levels in animal models .

• Clinical targets: Research supports IL-17A antibody applications in psoriasis, psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis .

How can I improve detection sensitivity in Western blots for IL-17A?

Western blot optimization for IL-17A requires attention to several parameters:

• Sample preparation: For optimal detection, analyze both whole cell lysates (WCL) and conditioned-media supernatants (Supe) from IL-17A-producing cells like differentiated Th17 cells .

• Membrane selection: PVDF membranes typically perform better than nitrocellulose for IL-17A detection .

• Buffer system: Use Immunoblot Buffer Group 1 for optimal results under reducing conditions .

• Antibody concentration: 1 μg/mL of affinity-purified antibody typically provides good signal-to-noise ratio .

• Expected band size: Human IL-17A appears at approximately 15 kDa under reducing conditions .

• Signal enhancement: HRP-conjugated secondary antibodies with enhanced chemiluminescence detection systems maximize sensitivity.

What are the key considerations for developing IL-17A-targeted therapeutics?

Development of IL-17A-targeted therapies involves multiple scientific considerations:

• Binding affinity: High-affinity antibodies like Indikizumab (KD=27.2 pM) demonstrate superior target engagement and biological effects .

• Epitope mapping: Comprehensive epitope mapping ensures target specificity and optimal neutralizing capacity .

• Neutralization potency: Cell-based neutralization assays comparing candidate antibodies to established standards (e.g., Secukinumab) provide critical functional data .

• In vivo efficacy models: Animal models such as the imiquimod-induced psoriasis mouse model provide proof-of-concept data on therapeutic potential .

• Biomarker selection: Tracking relevant biomarkers like KC levels helps quantify pharmacodynamic effects .

• Target specificity: Distinguishing between IL-17A and related isoforms ensures therapeutic specificity and potentially reduces off-target effects .